Kyntra Bio, Inc.
KYNB
$8.42
$0.384.73%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -1.47M | 3.74M | 1.28M | 1.08M | 1.35M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.47M | 3.74M | 1.28M | 1.08M | 1.35M |
| Cost of Revenue | 6.82M | 11.67M | 7.55M | 1.15M | 5.95M |
| Gross Profit | -8.30M | -7.93M | -6.27M | -75.00K | -4.60M |
| SG&A Expenses | 9.27M | 5.86M | 7.25M | 5.30M | 7.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.09M | 17.53M | 14.80M | 6.45M | 13.01M |
| Operating Income | -17.56M | -13.80M | -13.52M | -5.37M | -11.66M |
| Income Before Tax | 11.97M | -15.13M | -14.61M | -13.15M | -13.78M |
| Income Tax Expenses | -1.00K | -- | 0.00 | -- | -92.00K |
| Earnings from Continuing Operations | 11.97M | -15.13M | -14.61M | -13.15M | -13.68M |
| Earnings from Discontinued Operations | -- | -66.00K | 390.00K | 213.78M | 6.08M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.97M | -15.20M | -14.22M | 200.64M | -7.60M |
| EBIT | -17.56M | -13.80M | -13.52M | -5.37M | -11.66M |
| EBITDA | -17.56M | -13.79M | -13.51M | -5.18M | -11.44M |
| EPS Basic | 2.96 | -3.76 | -3.51 | 49.61 | -1.88 |
| Normalized Basic EPS | -2.93 | -2.33 | -2.26 | -1.01 | -2.07 |
| EPS Diluted | 2.96 | -3.76 | -3.51 | 49.61 | -1.88 |
| Normalized Diluted EPS | -2.93 | -2.33 | -2.26 | -1.01 | -2.07 |
| Average Basic Shares Outstanding | 4.05M | 4.05M | 4.05M | 4.04M | 4.04M |
| Average Diluted Shares Outstanding | 4.05M | 4.05M | 4.05M | 4.04M | 4.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |